Business Context and Reporting Period
This Form 6-K filing by Embraer S.A. covers the month of July 2014. The report details a strategic commercial agreement announced on July 15, 2014, at the Farnborough International Airshow. Embraer, the world's largest manufacturer of commercial jets up to 130 seats, operates across commercial aviation, executive aviation, and defense segments.
Key Financial Metrics and Order Details
The filing focuses on a specific firm order rather than comprehensive financial statements for the period.
- Firm Order: 3 E175 aircraft.
- Options: 3 additional E175 aircraft.
- Total Potential Value: USD 258.6 million (based on 2014 list prices if all options are exercised).
- Customer: Fuji Dream Airlines (FDA), a subsidiary of the Suzuyo Group in Japan.
- Backlog Status: The order was already included in Embraer's 2014 second-quarter backlog as an "undisclosed" customer.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period.
Material Changes and Strategic Developments
The primary material change is the formal disclosure of a previously undisclosed order, solidifying Embraer's relationship with Fuji Dream Airlines. Key developments include:
- Fleet Expansion: FDA currently operates three E170s and five E175s. This order supports the airline's strategy to expand its network and frequency in Japan's competitive domestic market.
- Technical Specifications: The new E175s will feature a single-class layout with 84 seats, the Autoland system for CAT III approaches, and aerodynamic enhancements (new wingtips) to reduce fuel burn.
- Service Agreement: FDA and Embraer signed an extension of the Pool Program, covering advance exchange and repair management for over 300 parts for the entire fleet, including new orders.
Outlook, Management Commentary, and Risks
Management Commentary: Yohei Suzuki (CEO, FDA) highlighted the efficiency, performance, and economics of the E-Jets as crucial to FDA's success. Paulo Cesar Silva (President & CEO, Embraer Commercial Aviation) noted that the order reflects FDA's prudent capacity management and that technical improvements will provide new economic benefits.
Future Outlook: Embraer continues to advance its second-generation E-Jets E2 family. The E190-E2 is scheduled to enter revenue service in the first half of 2018, followed by the E195-E2 in 2019 and the E175-E2 in 2020.
Risks and Contingencies: The filing includes a standard disclaimer regarding forward-looking statements. Risks include general economic, political, and trade conditions in Brazil and global markets; industry trends; investment plans; capacity to develop and deliver products; and governmental regulations. Actual results may differ substantially from expectations.
Investor Verification Checklist
- Verify the exercise status of the three E175 options included in the USD 258.6 million potential value.
- Confirm the impact of this order on the total backlog reported in the subsequent quarterly earnings release.
- Monitor the timeline for the entry into service of the E-Jets E2 family (E190-E2, E195-E2, E175-E2) as stated in the 2018-2020 schedule.
- Assess the competitive landscape in the Japanese domestic market regarding FDA's expansion plans.